SALT LAKE CITY, April 17, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2025 operating results on Wednesday, May 7, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day. Conference Call Details The conference call can be accessed by dialing 800-343-5172 for U.S. partici ...

SALT LAKE CITY, April 10, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite Spark™, a tailored data and analytics solution built for community health systems, regional hospitals, and multi-site practices. Smaller community health systems across the U.S. are navigating shrinking margins, policy uncertainty, and rising pressure to deliver ...

Core Insights - Health Catalyst (NASDAQ: HCAT) is highlighted as a valuable addition to the Bio Boom Portfolio, indicating its potential for growth and investment opportunity [1]. Company Overview - The article emphasizes the author's long-term investment in Health Catalyst, suggesting confidence in the company's future performance [2]. - The author has a background in healthcare investment, focusing on innovative companies that develop breakthrough therapies and pharmaceuticals [1]. Investment Strategy - The investment strategy includes a focus on companies with catalysts for potential acquisitions, which may enhance their market value [1].

Group 1 - The stock of Health Catalyst, Inc. (HCAT) is experiencing significant attention due to high implied volatility in the options market, particularly the Apr 17, 2025 $12.50 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in Health Catalyst's stock price, potentially due to an upcoming event [2] - Health Catalyst currently holds a Zacks Rank 3 (Hold) in the Medical Info Systems industry, which is in the top 17% of the Zacks Industry Rank, with no analysts increasing their estimates for the current quarter and two revising them downwards [3] Group 2 - The recent high implied volatility for Health Catalyst may indicate a trading opportunity, as options traders often seek to sell premium on options with high implied volatility, hoping the stock does not move as much as expected by expiration [4]

SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has repurchased shares of its common stock ("Common Stock") in an aggregate amount of approximately $5 million.These repurchased shares were acquired between March 3, 2025, and March 10, 2025, as part of Health Catalyst's existing share repurchase program approved by its board of directors on Au ...

Health Catalyst (HCAT) Q4 2024 Earnings Call February 27, 2025 06:40 AM ET Company Participants Jack Knight - VP - Investor RelationsDan Burton - CEODan Lesueur - COOJason Alger - Chief Financial OfficerJared Haase - Equity Research AssociateAnne Samuel - Executive DirectorSameer Patel - VP - Equity ResearchScott Schoenhaus - Managing DirectorGabrielle Ingoglia - Equity Research Associate Conference Call Participants Jessica Tassan - Senior Equity Research AnalystJohn Pinney - AnalystDaniel Grosslight - Sen ...

Core Insights - Health Catalyst reported revenue of $79.61 million for the quarter ended December 2024, reflecting a 6% increase year-over-year, but fell short of the Zacks Consensus Estimate of $79.83 million by 0.28% [1] - The company's EPS was $0.04, an increase from $0.02 in the same quarter last year, but significantly below the consensus estimate of $0.11, resulting in an EPS surprise of -63.64% [1] Revenue Breakdown - Professional services revenue was $28.01 million, slightly below the five-analyst average estimate of $29 million, with a year-over-year change of +0.1% [4] - Technology revenue reached $51.60 million, exceeding the five-analyst average estimate of $50.83 million, marking a year-over-year increase of +9.6% [4] Profitability Metrics - Adjusted Gross Profit for Professional Services was reported at $3.78 million, slightly below the average estimate of $3.81 million from five analysts [4] - Adjusted Gross Profit for Technology was $33.35 million, surpassing the average estimate of $32.89 million from five analysts [4] Stock Performance - Over the past month, shares of Health Catalyst have returned -14.7%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - Health Catalyst (HCAT) reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share, but showing an improvement from $0.02 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was -63.64%, with a previous quarter's earnings of $0.07 per share also missing expectations of $0.10 per share, resulting in a -30% surprise [2] - Health Catalyst's revenues for the quarter ended December 2024 were $79.61 million, slightly missing the Zacks Consensus Estimate by 0.28%, compared to $75.08 million in the same quarter last year [3] - Over the last four quarters, the company has surpassed consensus revenue estimates two times [3] Stock Performance - Health Catalyst shares have declined approximately 30% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $82.64 million, and for the current fiscal year, it is $0.38 on revenues of $338.89 million [8] - The estimate revisions trend for Health Catalyst is mixed, and changes in earnings expectations may occur following the recent earnings report [7] Industry Context - The Medical Info Systems industry, to which Health Catalyst belongs, is currently ranked in the bottom 49% of over 250 Zacks industries, suggesting potential challenges ahead [9] - The performance of Health Catalyst may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Client Engagement and Growth - Health Catalyst has generated over 1,800 documented, client-verified improvements across clinical, financial, and operational domains, enabling substantial clinical improvements, financial savings, or operational efficiencies[38] - The company aims to grow its client base, targeting over 1,200 healthcare organizations, and plans to expand into international markets including Singapore, the UK, and Saudi Arabia[50] - As of December 31, 2024, the company served 130 Platform Clients and over 900 App Clients, with a focus on clients signing technology contracts with at least $100,000 of incremental total ARR and non-recurring revenue[39] - Health Catalyst's clients primarily include healthcare providers who utilize the company's solutions to manage data and derive analytical insights[19] - The company expects to derive a significant portion of revenue from the renewal of existing client contracts and sales of additional technology and services, which are critical for future growth[149] - Clients may terminate contracts before expiration for various reasons, including dissatisfaction with service levels, which could adversely affect future revenue[150] Innovation and Product Development - The company aims to expand its service offerings and develop new platform features, particularly through the rollout of Health Catalyst Ignite[16] - The Ignite Data & Analytics Platform is a healthcare-specific, cloud-based ecosystem that integrates and organizes data from disparate software systems, enabling clients to achieve measurable improvements across clinical, financial, and operational domains[39][41] - The Ignite platform supports both Health Catalyst solutions and client-developed applications, allowing for rapid product iteration and deployment[41] - The company focuses on continuous R&D to enhance usability and functionality of its solutions, responding to client feedback and market needs[78] - The company has developed a comprehensive suite of applications that leverage a data asset of over 100 million patient records to uncover actionable insights for clients[56] Financial Performance and Revenue - The recurring revenue subscription model provides high revenue visibility, with a Dollar-based Retention Rate for Platform Clients maintained at 100% for the years ended December 31, 2024, 2023, and 2022[43][50] - The company derives a significant portion of its revenue from its largest clients, with the three largest clients in 2024 accounting for 13.8% of total revenue, compared to 12.6% in 2023[174] - The company recognizes technology and professional services revenue ratably over the term of contracts, which may delay the impact of downturns in business on reported results[177] - A significant portion of operating expenses is fixed in nature, leading to potential decreases in gross margins and profitability if unexpected revenue shortfalls occur[155] Market and Competitive Environment - The company operates in a highly competitive environment, and failure to innovate could adversely affect revenue and results of operations[18] - The company faces intense competition in the healthcare solutions market, impacting its ability to maintain or expand its client base[121] - Changes in the healthcare industry could negatively affect demand for the company's solutions and complicate contract negotiations[125] - The company must continue to innovate and adapt to market changes to remain competitive, as failure to do so could negatively impact revenue and operations[146] Regulatory and Compliance Challenges - The company emphasizes compliance with evolving data privacy and security laws, which govern the handling of health-related personal information[85] - Compliance with evolving federal and state laws and regulations may require significant changes to business practices, potentially incurring substantial costs[94] - The FDA regulates certain medical software as medical devices, which may require premarket clearance or approval depending on the risk classification[95] - The company operates in a regulatory environment that may require compliance with additional laws and regulations as new services are introduced[94] - The company is subject to evolving regulatory frameworks for AI Technologies, which may require significant resources to ensure compliance and could increase operating expenses[171] Team Member Engagement and Culture - Client engagement is a priority, with a focus on attracting, developing, and retaining highly-qualified employees, which is essential for long-term success[21] - The company emphasizes the importance of team member engagement, achieving a consistent ranking in the 94th to 99th percentile as measured by Gallup[22] - The company emphasizes team member engagement as a top priority, which is foundational to its operational success and client relationships[107] - The company has received 110 recognitions as a "best place to work" from various organizations, reflecting strong team member engagement[76] Risks and Challenges - Macroeconomic challenges, including high inflation and interest rates, could impact the company's financial condition and results of operations[18] - The company may face increased software development and administrative expenses if it needs to update services to comply with changing interoperability standards[93] - Cybersecurity threats pose risks to the company’s information technology systems, potentially leading to data breaches and operational disruptions[196] - Unauthorized access or security breaches could result in loss of information, litigation, and damage to reputation[199] Acquisitions and Growth Strategy - The company has a history of acquisitions to enhance its product portfolio, including notable acquisitions such as Medicity and Vitalware, which have contributed to its growth strategy[50] - The company has acquired multiple businesses between January 1, 2020, and January 31, 2025, including Able Health, Healthfinch, and others, which may pose integration challenges and affect financial performance[182] - Future acquisitions could lead to dilutive equity issuances or increased debt, adversely impacting the company's financial condition and results of operations[184] Management and Organizational Structure - The management team consists of healthcare and data veterans with extensive experience in leading digital transformation in health systems, underpinning the company's strategic direction[48] - The company’s success is heavily dependent on its senior management team, and any loss of key executives could disrupt operations and delay business objectives[186] - The company must effectively manage organizational changes and growth to avoid operational mistakes and ensure client satisfaction[190]

Revenue Performance - Total revenue for the full year 2024 was $307 million, with a 4% increase compared to $295.9 million in 2023[2] - Total revenue for Q4 2024 reached $79.606 million, a 6.7% increase from $75.084 million in Q4 2023[20] - For the twelve months ended December 31, 2024, total revenue was $306,584,000, a 3.4% increase from $295,938,000 in 2023[34][37] Segment Performance - Technology segment revenue reached $195 million for the full year 2024, representing a 10% year-over-year growth[2] - Technology revenue increased to $51.598 million, up 9.5% from $47.100 million year-over-year[20] Profitability Metrics - Adjusted EBITDA for the full year 2024 was $26 million, a 137% increase from $11 million in 2023[2] - Adjusted EBITDA for Q4 2024 was $7,911,000, compared to $1,352,000 in Q4 2023, indicating significant operational improvement[39] - Adjusted Gross Profit for 2024 was calculated by excluding non-cash expenses, providing a clearer view of operational performance[27] - Adjusted Gross Profit for Q4 2024 was $37,121,000, representing an increase of 7.3% from Q4 2023's adjusted gross profit of $34,693,000[30][32] - Adjusted Gross Margin for Q4 2024 improved to 47%, up from 46% in Q4 2023[30][32] - Adjusted Gross Profit for the twelve months ended December 31, 2024, was $149,533,000, compared to $144,060,000 in 2023, reflecting a growth of 3.1%[34][37] - Adjusted Gross Margin for the twelve months ended December 31, 2024, was 49%, consistent with the previous year's margin[34][37] Net Loss and Improvements - The company reported a net loss of $20.7 million for Q4 2024, a 32% improvement compared to a net loss of $30.3 million in Q4 2023[3] - Net loss for Q4 2024 was $20,673,000, an improvement from a net loss of $30,312,000 in Q4 2023[20] - The net loss for the full year 2024 was $69.502 million, an improvement from a net loss of $118.147 million in 2023[42] Cash and Assets - Cash and cash equivalents as of December 31, 2024, were $249.6 million, compared to $106.3 million in 2023[18] - Total assets increased to $858.9 million in 2024, up from $701.8 million in 2023[18] - Cash and cash equivalents at the end of Q4 2024 were $249.645 million, significantly up from $106.276 million at the end of Q4 2023[26] Client and Retention Metrics - The number of Platform Clients increased to 130 in 2024, up from 109 in 2023[7] - The Dollar-based Retention Rate for Tech + TEMS was 102% as of December 31, 2024[7] Cost Management - Operating expenses decreased to $52.191 million in Q4 2024, down from $63.293 million in Q4 2023, reflecting a 17.4% reduction[20] - Stock-based compensation expense for the year 2024 totaled $40.128 million, down from $55.756 million in 2023[26] - Acquisition-related costs for Q4 2024 totaled $4,333,000, up from $2,655,000 in Q4 2023, reflecting ongoing integration efforts[39] - Restructuring costs in Q4 2024 were $0, down from $6,767,000 in Q4 2023, indicating a stabilization in workforce-related expenses[39] - Non-cash interest expense related to debt for the full year 2024 was $3.256 million, up from $1.511 million in 2023[42] Future Outlook - The company raised its 2025 Adjusted EBITDA target to approximately $41 million, an increase of $2 million from previous guidance[2] - The company plans to continue focusing on market expansion and new product development to drive future growth[20] - The company aims to improve operational performance by focusing on eliminating non-recurring charges and enhancing core business metrics[42]